 | | Vol. 24.07 – 6 March, 2023 |
| |
|
|
| This randomized, double-blind, multicenter study evaluated a single transendocardial administration procedure of mesenchymal precursor cells or sham-control in 565 intention-to-treat patients with heart failure with reduced ejection fraction on guideline-directed therapies.
[Journal Of The American College Of Cardiology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In vivo tumor reprogrammed-antigen presenting cells induction elicited clonal expansion of cancer-specific T cells, established cancer-specific immune memory, and ultimately promoted leukemia eradication.
[Cancer Discovery] |
|
|
|
| Investigators explored an approach in which allogeneic islets were transplanted onto the omentum, which was bioengineered with a plasma-thrombin biodegradable matrix in three diabetic non-human primates.
[Cell Reports Medicine] |
| |
|
|
A novel bionic tissue-engineered nerve graft with a biomimetic structure and composition was designed, which included a chitin helical scaffold which was fabricated by means of mold casting and acetylation using chitosan as the raw material.
[Advanced Healthcare Materials] |
|
|
|
| Scientists provided evidence that caspase-dependent apoptotic cell death of neural stem and progenitor cells was required for sending survival signals to the injured brain.
[Cell Death & Disease] |
|
|
|
| Investigators reported that mesothelin-specific TRuC-T cells potently killed MSLN+ tumor cells in vitro and efficiently eradicated MSLN+ mesothelioma, lung, and ovarian cancers in xenograft mouse tumor models.
[Oncoimmunology] |
|
|
|
| Researchers described the implantation in mouse of engineered human mature microvasculature consisting of endothelial and perivascular cells embedded in collagen hydrogel that allowed investigation of pathogen interactions with the endothelium, including in vivo functional studies.
[iScience] |
|
|
|
| Investigators analyzed SARS-CoV-2-S-RA kinetics at 3–6 weeks, 3 months, and 6 months after a full course of SARS-CoV-2 vaccination and after additional vaccine doses, in a prospective monitored cohort of allo-HSCT, ASCT, and CAR-T cell therapy recipients.
[Bone Marrow Transplantation] |
|
|
|
| Scientists explored combinatorial therapy by the use of anti-CD19 CAR-T immunotherapy and gallic acid for improving treatment efficacy.
[Molecular Biomedicine] |
|
|
|
|
| The authors describe the current application of CAR T-cell therapy in treating high-grade gliomas, as there are still many challenges that need to be addressed to optimize the safety and efficacy of CAR T-cell therapy.
[Immunotherapy] |
|
|
|
|
| Nexcella, Inc. announced 50 relapsed/refractory multiple myeloma patients had already been dosed with next-generation CAR-T NXC-201 in its ongoing Phase Ib/IIa clinical trial. Nexcella anticipated 100-patient open-label total enrollment to seek US FDA BLA approval.
[Nexcella, Inc.(Globe Newswire)] |
|
|
|
|
| March 15 – 18, 2023
Denver, Colorado, United States |
|
|
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | ETH Zurich – Zurich, Switzerland |
|
|
|
| | Rutgers Cancer Institute of New Jersey – New Brunswick, New Jersey, United States |
|
|
|
| | The Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus – Frankfurt, Germany |
|
|
|
| | The University of Melbourne – Melbourne, Australia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
